Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
P53803
UPID:
RPAB4_HUMAN
Alternative names:
ABC10-alpha; DNA-directed RNA polymerase II subunit K; RNA polymerase II 7.0 kDa subunit; RPB10alpha
Alternative UPACC:
P53803; Q6IBD4
Background:
DNA-directed RNA polymerases I, II, and III subunit RPABC4, known by alternative names such as ABC10-alpha and RPB10alpha, plays a pivotal role in the transcription process. It catalyzes the transcription of DNA into RNA, utilizing ribonucleoside triphosphates as substrates. This protein is a common component of RNA polymerases I, II, and III, which are essential for synthesizing ribosomal RNA precursors, mRNA precursors, functional non-coding RNAs, and small RNAs like 5S rRNA and tRNAs.
Therapeutic significance:
Understanding the role of DNA-directed RNA polymerases I, II, and III subunit RPABC4 could open doors to potential therapeutic strategies.